C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer.

Humans Female B7-H1 Antigen Immune Checkpoint Inhibitors / pharmacology Tumor Microenvironment Prognosis Ovarian Neoplasms / drug therapy
High-grade serous ovarian cancer immunotherapy prognosis tumor microenvironment tumor-associated macrophages

Journal

Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526

Informations de publication

Date de publication:
2023
Historique:
medline: 5 10 2023
pubmed: 4 10 2023
entrez: 4 10 2023
Statut: epublish

Résumé

High-grade serous ovarian cancer (HGSC), with a modest response to immune checkpoint blockade (ICB) targeting PD-1/PD-L1 monotherapy, is densely infiltrated by M2-polarized tumor-associated macrophages (TAMs) and regulatory T (Treg) cells. The complement C5a/C5aR1 axis contributes to the programming of the immunosuppressive phenotype of TAMs in solid tumors and represents a promising immunomodulatory target for treating HGSCs. Here, we aimed to identify the relevance of C5aR1 in prognosis, immune microenvironment, and immunotherapy response in HGSCs. The expression and relationship of C5aR1 with tumor-infiltrating immune cells were assessed by immunohistochemistry and flow cytometry in the training cohort (

Identifiants

DOI: 10.1080/2162402X.2023.2261242 PMID: 37791232 PMC: PMC10543342
pubmed: 37791232
doi: 10.1080/2162402X.2023.2261242
pii: 2261242
pmc: PMC10543342
doi:

Substances chimiques

B7-H1 Antigen 0
Immune Checkpoint Inhibitors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2261242

Informations de copyright

© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.

Déclaration de conflit d'intérêts

No potential conflict of interest was reported by the author(s).

Références

Eur Urol. 2022 Apr;81(4):331-336
pubmed: 35086719
J Immunol. 2013 Apr 15;190(8):3839-47
pubmed: 23564578
Exp Mol Pathol. 2016 Feb;100(1):101-8
pubmed: 26475622
Oncol Rep. 2015 Apr;33(4):1844-50
pubmed: 25682807
Cancer Cell. 2022 May 9;40(5):545-557.e13
pubmed: 35427494
J Immunol. 2012 Dec 15;189(12):5533-40
pubmed: 23125418
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32900861
Nature. 2014 Mar 27;507(7493):462-70
pubmed: 24670764
J Exp Med. 2013 Feb 11;210(2):257-68
pubmed: 23382542
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
J Transl Med. 2017 Mar 30;15(1):66
pubmed: 28359318
Oncol Lett. 2016 Nov;12(5):3995-4000
pubmed: 27895761
Ann Oncol. 2019 Jul 1;30(7):1080-1087
pubmed: 31046082
Cancer Res. 2012 Jul 15;72(14):3570-81
pubmed: 22581824
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Mol Cell Proteomics. 2014 Feb;13(2):397-406
pubmed: 24309898
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
Nat Rev Immunol. 2008 Sep;8(9):699-712
pubmed: 18728635
Nat Rev Immunol. 2018 Jan;18(1):5-18
pubmed: 28920587
Nat Rev Cancer. 2015 Aug;15(8):457-72
pubmed: 26205340
Cancer Res. 2020 Oct 15;80(20):4335-4345
pubmed: 32747365
J Immunol. 2012 Nov 1;189(9):4674-83
pubmed: 23028051
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Int J Biol Sci. 2012;8(7):964-78
pubmed: 22811618
Mol Immunol. 2009 Sep;46(14):2753-66
pubmed: 19477527
Front Immunol. 2019 Apr 03;10:669
pubmed: 31001273
Cancer Res. 2014 Jul 1;74(13):3454-65
pubmed: 24786787
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Immunity. 2014 Apr 17;40(4):569-81
pubmed: 24745333
Cancer Discov. 2015 Dec;5(12):1262-70
pubmed: 26370156
Nat Immunol. 2008 Nov;9(11):1225-35
pubmed: 18820683
Nat Med. 2018 Oct;24(10):1550-1558
pubmed: 30127393
Eur J Immunol. 1990 Feb;20(2):253-7
pubmed: 1690130
J Immunol. 2011 Dec 1;187(11):5805-12
pubmed: 22058413
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
JAMA Oncol. 2019 Mar 1;5(3):393-401
pubmed: 30676622
Cancer Res. 2023 Jul 5;83(13):2171-2186
pubmed: 37172314
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
J Biol Chem. 2005 Dec 2;280(48):39677-80
pubmed: 16204243
Breast Cancer. 2016 Nov;23(6):876-885
pubmed: 26494574
Oncoimmunology. 2013 Mar 1;2(3):e23337
pubmed: 23802077
J Immunol. 2012 Sep 15;189(6):2985-94
pubmed: 22914051
Nat Rev Cancer. 2019 Dec;19(12):698-715
pubmed: 31666715
Cancer Res. 2005 Feb 1;65(3):1089-96
pubmed: 15705911
Lung Cancer. 2013 Aug;81(2):259-65
pubmed: 23706417
J Natl Compr Canc Netw. 2022 Sep;20(9):972-980
pubmed: 36075393
Cell Commun Signal. 2013 Jan 14;11:4
pubmed: 23317458
Genome Biol. 2016 Nov 17;17(1):231
pubmed: 27855702
Nat Immunol. 2010 Sep;11(9):785-97
pubmed: 20720586
Oncotarget. 2016 Dec 20;7(51):84798-84809
pubmed: 27756879
Clin Cancer Res. 2008 Aug 15;14(16):5198-208
pubmed: 18698038

Auteurs

Chen Zhang (C)

Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.

Kankan Cao (K)

Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.

Moran Yang (M)

Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.

Yiying Wang (Y)

Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.

Mengdi He (M)

Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.

Jiaqi Lu (J)

Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.

Yan Huang (Y)

Department of Gynecologic Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China.

Guodong Zhang (G)

Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
Department of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.

Haiou Liu (H)

Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
ORCID: 0000-0003-0200-8981

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › C5aR1 blockade reshapes immunosuppressive...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Antigènes B7 › Antigène CD274 › C5aR1 blockade reshapes immunosuppressive...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Antinéoplasiques immunologiques › Inhibiteurs de points de contrôle immunitaires › C5aR1 blockade reshapes immunosuppressive...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › C5aR1 blockade reshapes immunosuppressive...
questionsmedicales.fr › Diagnostic › Pronostic › C5aR1 blockade reshapes immunosuppressive...
questionsmedicales.fr › Maladies endocriniennes › Troubles gonadiques › Maladies ovariennes › Tumeurs de l'ovaire › C5aR1 blockade reshapes immunosuppressive...